14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BLPH ranks #15678 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Bellerophon Therapeutics Stock Forecast NASDAQ:BLPH

$2.73 (-2.15%)

Volume: 46k

Closed: Jan 19, 2022

Hollow Logo Score: -4.240

Bellerophon Therapeutics Stock Forecast

$2.73 (-2.15%)

Volume: 46k

Closed: Jan 19, 2022

Score Hollow Logo -4.240

Bellerophon Therapeutics Company Profile

184 Liberty Corner Road

Warren NJ 07059



Industry: Biotechnology

Sector: Healthcare


Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates include INOpulse, a pulsatile nitric oxide delivery device, which has completed Phase II clinical trials for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE